JP2001508430A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508430A5
JP2001508430A5 JP1998530400A JP53040098A JP2001508430A5 JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5 JP 1998530400 A JP1998530400 A JP 1998530400A JP 53040098 A JP53040098 A JP 53040098A JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998530400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508430A (ja
Filing date
Publication date
Priority claimed from US08/779,767 external-priority patent/US6737057B1/en
Application filed filed Critical
Publication of JP2001508430A publication Critical patent/JP2001508430A/ja
Publication of JP2001508430A5 publication Critical patent/JP2001508430A5/ja
Ceased legal-status Critical Current

Links

JP53040098A 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法 Ceased JP2001508430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/779,767 US6737057B1 (en) 1997-01-07 1997-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US08/779,767 1997-01-07
PCT/US1998/000520 WO1998030706A1 (en) 1997-01-07 1998-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors

Publications (2)

Publication Number Publication Date
JP2001508430A JP2001508430A (ja) 2001-06-26
JP2001508430A5 true JP2001508430A5 (enExample) 2005-09-08

Family

ID=25117492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53040098A Ceased JP2001508430A (ja) 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法

Country Status (6)

Country Link
US (2) US6737057B1 (enExample)
EP (1) EP1012308A1 (enExample)
JP (1) JP2001508430A (enExample)
AU (1) AU744885B2 (enExample)
CA (1) CA2277582A1 (enExample)
WO (1) WO1998030706A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
AU5090899A (en) * 1998-07-06 2000-01-24 University Of Tennessee Research Corporation, The Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2340085A1 (en) * 1998-08-10 2000-02-24 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
EP1964854A2 (en) * 1999-10-27 2008-09-03 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
EP1598370A3 (en) * 1999-10-27 2006-05-10 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE60123238T2 (de) * 2000-06-05 2007-05-03 University of Tennessee Corp., Knoxville Zusammensetzungen zur behandlung von autoimmunkrankheiten
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
EP1499346B1 (en) 2002-04-09 2008-01-02 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US7744876B2 (en) * 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
CA2526950C (en) * 2002-05-27 2012-06-26 Leif Hakansson Method for determining immune system affecting compounds
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
SE0402536D0 (sv) * 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
WO2006110091A1 (en) * 2005-04-15 2006-10-19 Therim Diagnostica Ab Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
DK3130602T3 (da) 2007-05-08 2019-11-04 Canimguide Therapeutics Ab Immunregulerende strukturer fra normalt forekommende proteiner
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
AU616338B2 (en) 1989-02-02 1991-10-24 Mato Maschinen- Und Metallwarenfabrik Curt Matthaei Gmbh & Co Kg Belt skimming device
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
JPH06511241A (ja) 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994014847A1 (en) 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996034622A1 (en) 1995-05-02 1996-11-07 Alexion Pharmaceuticals, Inc. Modified myelin protein molecules
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2003524369A (ja) 1997-08-19 2003-08-19 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー エピトープを有する主要組織適合複合体クラスｉｉエレメント／免疫グロブリンキメラ分子

Similar Documents

Publication Publication Date Title
JP2000509637A5 (enExample)
JP2000510751A5 (enExample)
JP2002510447A5 (enExample)
JP2000507042A5 (enExample)
JP2000509942A5 (enExample)
JP2001509070A5 (enExample)
JP2001515619A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2002512601A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2001513765A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)